An expert panel calls the requirement for tuberculosis testing before prescribing IL-17 and IL-23 biologics for psoriasis an ...

Routine testing for latent tuberculosis infection is not required for patients receiving interleukin-17 or -23 inhibitors for psoriasis, according to an updated position statement. “When IL-17 and ...

Acute psoriasis on elbows is an autoimmune incurable dermatological skin disease. Large red, inflamed, flaky rash on the knees. Joints affected by psoriatic arthritis. The long-term persistence of ...

Patients with psoriasis or psoriatic arthritis who are newly treated with IL-12/23 blockers demonstrated a reduced risk for serious infection compared with those who received TNF or IL-17 inhibitors, ...

In patients with psoriasis or ankylosing spondylitis, the use of interleukin (IL)-17A inhibitors, particularly secukinumab, was associated with an increased risk for inflammatory bowel disease (IBD) ...

Eligible trials included those evaluating IL-17 or IL-23 inhibitors for PsO and documented PASI scores. Interleukin-17 (IL-17) inhibitors demonstrated faster psoriasis (PsO) clearance than Interleukin ...

Patients with inflammatory/autoimmune diseases who initiated treatment with interleukin (IL)-17 inhibitors did not have a higher risk for the development of ...

In a deal worth $2.4 billion in cash, Eli Lilly and Co. agreed to acquire Dice Therapeutics Inc., gaining a franchise of oral IL-17 inhibitors for chronic autoimmune diseases.

Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also ...

Authors of an observational cohort study published in the Journal of the European Academy of Dermatology and Venereology investigated the efficacy of interleukin-17 inhibitors (IL-17i) for the ...